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OBJECTIVES: Emergency room (ER) visits are perceived with the high costs and 
unpredictable outcomes. Although the association between Attention Deficit 
Hyperactivity Disorder (ADHD), stimulants and ER visits has been studied; differ-
ence between the types of stimulants in terms of risk of ER visits have not been 
studied. Our objective is to identify the difference between the effects of long act-
ing and short acting stimulant use in ADHD on ER visits in 18 to 35 year old adults 
(n= 636) in the year 2011. METHODS: This retrospective secondary data analysis 
used the Medical Expenditure Panel Survey (MEPS) data for the year 2011. Univariate 
and Multivariate logistic regression were used to evaluate risk factors influencing 
type of stimulant use on ER visits. Risk factor and stimulant interactions were also 
included. RESULTS: The risk of ER visits in long acting stimulant users, among 
the uninsured, on adjusting for race, marital and insurance status, is 14.25 times 
(p= 0.001) the risk of ER visits in short acting stimulant users. If they are insured, 
the risk of ER visits in long acting stimulant users is 1.83 times the risk of ER visits 
in short acting stimulant users (p= 0.26). CONCLUSIONS: Long-acting stimulants 
combined with lack of insurance is a risk factor for increased ER visits. Our results 
support Affordable Care Act’s efforts for the requirements of expansion on coverage 
in mental disorders to reach better healthcare outcome.
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OBJECTIVES: The long-acting injectable aripiprazole once-monthly 400 mg (AOM 
400) has been approved for treatment of schizophrenia in Finland since November 
2013. Other atypical anti-psychotics, risperidone, paliperidone and olanzapine are 
also available as long-acting injectable formulations. A mixed treatment comparison 
has demonstrated that AOM 400 is at least as efficacious as other atypical long-
acting anti-psychotics (ALAIs). However, cost of administration and drug (treatment 
cost) vary among the ALAIs. This analysis aims to investigate the total treatment 
costs of ALAIs using real-world data in Finland. METHODS: A one-year time horizon 
budget impact analysis was conducted to compare the treatment costs of ALAIs in 
Finland. The real-world doses were calculated using sales data. One of the ALAIs 
(olanzapine) can be given in intervals of 2 or 4 weeks using the 300 mg strength. Half 
of the patients were assumed treated with the 300 mg dose every 2 weeks, the other 
half every 4 weeks. Prices for ALAIs were obtained from the official national price 
list. The cost of administration for AOM 400, paliperidone-LAI and risperidone-LAI 
was based on the cost of a short nurse visit (30 minutes) to a psychiatry outpatient 
clinic. The cost of administration of olanzapine-LAI was based on the cost of a longer 
visit (120-180 minutes), as the product information recommends monitoring for 
three hours after injection. RESULTS: The expected cost for drug and administration 
per patient, per year, for AOM 400 is 5158 EUR. The expected yearly costs per patient 
for drug and administration for paliperidone-LAI, risperidone-LAI and olanzapine-
LAI are 6021 EUR, 6706 EUR and 11646 EUR respectively. CONCLUSIONS: In a budget 
impact analysis, using the method, data and assumptions described, AOM 400 is 
expected to be cost saving, in the real-world setting, in terms of cost of drug and 
administration, compared to other ALAIs available in Finland.
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OBJECTIVES: To compare healthcare utilization and costs between early- and 
late-stage Alzheimer’s disease (AD) patients residing in long-term care (LTC) 
facilities. METHODS: Patients diagnosed with AD (International Classification of 
Diseases, 9th Revision, Clinical Modification [ICD-9-CM] code 331.0) were identified 
using U.S. Medicare claims linked with the Long-Term Care Minimum Data Set (MDS) 
from 01JULY2008 through 31DEC2010. The first diagnosis date was designated as 
the index date. Patients were required to be age ≥ 65 years, with continuous medical 
and pharmacy benefits for 6 months pre- and post-index date, and reside in an LTC 
facility. Patients were categorized as early- or late-stage. Late-stage AD was defined 
by a cognitive performance scale score ≥ 5 (range 0-6) and Activities of Daily Living 
short-form activities score ≥ 10 points. Patients with and without AD were matched 
based on demographic and clinical characteristics, and 1:1 propensity score match-
ing was used to compare follow-up all-cause and AD-related healthcare costs and 
utilizations. RESULTS: Before matching, late-stage AD patients (n= 5,323) were less 
likely to be white (83.0% vs. 86.4%), male (16.4% vs. 21.7%) and have comorbid condi-
tions measured by the Charlson Comorbidity Index score (3.55 vs. 4.83, p< 0.001) than 
early-stage AD patients (n= 20,023). After 1:1 matching, 3,804 patients were matched 
from each cohort and baseline characteristics were balanced. Fewer late-stage AD 
patients had skilled nursing facility admissions (25.3% vs. 29.8%, p< 0.0001), but more 
had hospice admissions (17.8% vs. 7.3%, p< 0.0001) and pharmacy visits (85.8% vs. 
81.9%, p< 0.0001) than early-stage AD patients. There were no significant differences 
in total all-cause healthcare costs; however, late-stage AD patients incurred signifi-
cantly higher disease-related total ($14,739 vs. $13,673, p= 0.0242) and hospice costs 
($4,157 vs. $1,553, p< 0.0001) compared to early-stage AD patients. CONCLUSIONS: 
Patients with late-stage AD incurred higher disease-related costs than those with 
early-stage AD; however, there were no significant differences in total all-cause 
healthcare costs.
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OBJECTIVES: Pharmacy databases can yield important information about drug uti-
lization and costs. This study sought to examine changes in prescription utilization 
and costs among atypical antipsychotic (AAP) subjects initiating lurasidone or ari-
piprazole therapy. METHODS: Adults filling lurasidone or aripiprazole prescriptions 
from 2/3/2011—6/30/2013 were identified in the Walgreens pharmacy-database. 
Treatment-naive monotherapy subjects (no AAP prescriptions before-and-after 
index prescription) with ≥ 12-months pre-/post-index continuous enrollment 
were eligible. Lurasidone subjects were compared to a 1:1 matched random sam-
ple of aripiprazole subjects. Baseline demographics and health-insurance status 
were compared between cohorts. Mental-health prescriptions (antianxiety agents, 
antidepressants, antipsychotics, psychotherapeutic, and neurologic agents) were 
identified using Generic Product Identifier for the National Drug Code numbers on 
pharmacy claims. Differences in mean changes (post-pre) in all-cause prescrip-
tion fills all-cause prescription costs, mental-health prescription fills and mental-
health costs were compared using t-tests. RESULTS: Each cohort included 4,595 
subjects (lurasidone vs aripiprazole: 69.3% vs 72.2% female, mean ages 41.0 vs 43.4 
years). Most subjects were commercially-insured (39.9% vs 48.6%), followed by State-
Medicaid (24.4% vs 18.7%), Medicare-Part-D (22.8% vs 18.7%), and Managed-Medicaid 
(6.8% vs 5.6%). Lurasidone subjects had lower 30-day equivalent co-pays ($42.02 vs 
$56.63). Subjects were more likely to be prescribed lurasidone by psychiatrists (78.0% 
vs 57.3%) and less likely by general-practitioners (3.1% vs 23.0%). Overall, lower 
mean increases in all-cause prescription fills (11.3 vs 12.3;p= .09) and mental-health 
prescription fills (7.2 vs 8.0;p< .01) were observed for lurasidone than aripiprazole 
subjects. Additionally, mean differences in all-cause prescription costs ($2,388 vs 
$3,080;p< .01) and mental-health prescription costs ($2,123 vs $2,810;p< .01) were 
lower for lurasidone than aripiprazole subjects. Similar patterns of mean changes in 
prescription utilization and costs were found in commercial, Medicaid and Medicare 
subjects. CONCLUSIONS: In this national-US pharmacy-database analysis compar-
ing subjects initiating branded AAPs, lurasidone subjects had fewer mean changes in 
all-cause and mental-health prescriptions and lower mean increases in associated 
costs than aripiprazole subjects.
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OBJECTIVES: Dementia is associated with high costs of national healthcare in 
European countries. Disruptive neuropsychiatric symptom (NPS) such as agitation 
and aggression (A/A), increase caregiver burden, lead to premature institutionaliza-
tion and death, and increase dementia costs. The aim of this study is to estimate 
the incremental societal costs for Patients with Dementia (PwD) with A/A in both 
Community-Dwelling (CD) and long-term care (LTC) settings in 8 European coun-
tries. METHODS: This study uses data fromthe RightTimePlaceCare (RTPC) European 
project. Interviews using structured questionnaires are conducted with 2014 PwD 
and their primary informal caregivers. Direct and informal costs are estimated from 
a societal perspective. Resource utilization is assessed with the resource utilization 
in dementia instrument. Resource consumption is valued using unit costs for each 
country, the replacement cost approach (informal care) and retail prices (medica-
tion).To estimate incremental costs of A/A, costs for PwD with A/A are compared 
to costs for PwD without A/A in both settings. Special emphasis is placed on the 
main predictors of costs. RESULTS: 2002 patients completed agitation item into 
the NeuroPsychiatric Inventory-Questionnaire at baseline (i.e. 1219 CD and 883 
LTC). For CD patients with A/A societal costs are 2,472€ for one month vs. 2,144€ 
for patient without A/A (p= 0.002). Incremental costs of A/A for CD patients are 
mainly due to informal costs and inpatient costs which are+174€ (p= 0.015) and 
+113€ (p= 0.048), respectively. For LTC patients with A/A societal costs are 4,730€ for 
one month vs. 4,166€ for patients without A/A (p= 0.003). Incremental costs of A/A 
for LTC patients are mainly due to nursing home costs and outpatient costs which 
are +353€ (p= 0.003) and +148€ (p= 0.000), respectively. CONCLUSIONS: A/A in PwD 
living at home or in LTC setting increase societal costs by 15%.
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OBJECTIVES: Schizoaffective disorder, with both mood and psychotic symptoms, 
may necessitate different treatment than other schizophrenia subtypes. Long-
acting injectable antipsychotics may reduce hospitalizations among schizophrenia 
patients but generalizability to schizoaffective disorder is unclear. This study com-
